Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 16;13(16):4119.
doi: 10.3390/cancers13164119.

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future

Walid Shalata  1 , Binil Mathew Jacob  2 , Abed Agbarya  3
Affiliations
Review

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future

Walid Shalata et al. Cancers (Basel). .

Abstract

Lung cancer is the most common malignancy across the world. The new era in lung cancer treatments, especially this past decade, has yielded novel categories of targeted therapy for specific mutations and adjuvant therapy, both of which have led to improved survival rates. In the present study, we review the changes and development of treatments, with a special focus on adjuvant therapy using tyrosine kinase inhibitors (TKIs) administered to non-small-cell lung carcinoma patients who had a complete resection of the tumor harboring a mutated epidermal growth factor receptor. The clinical trials are dating from the past (chemotherapy trials), present (TKIs), and future (ongoing trials).

Keywords: adjuvant treatment; epidermal growth factor receptor (EGFR); lung cancer; non-small-cell lung carcinoma (NSCLC); tyrosine kinase inhibitor (TKI).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Miller K.D., Nogueira L., Mariotto A.B., Rowland J.H., Yabroff K.R., Alfano C.M., Jemal A., Kramer J.L., Siegel R.L. Cancer Treatment and Survivorship Statistics, 2019. CA Cancer J. Clin. 2019;69:363–385. doi: 10.3322/caac.21565. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2019. CA Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Duma N., Santana-Davila R., Molina J.R. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin. Proc. 2019;94:1623–1640. doi: 10.1016/j.mayocp.2019.01.013. - DOI - PubMed
    1. Fischer B.M., Mortensen J., Hansen H., Vilmann P., Larsen S.S., Loft A., Bertelsen A.K., Ravn J., Clementsen P., Høegholm A., et al. Multimodality Approach to Mediastinal Staging in Non-Small Cell Lung Cancer. Faults and Benefits of PET-CT: A Randomised Trial. Thorax. 2011;66:294–300. doi: 10.1136/thx.2010.154476. - DOI - PubMed